2024
Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes
Volovsky M, Seifer D. Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes. Journal Of Clinical Medicine 2024, 13: 3739. PMID: 38999305, PMCID: PMC11242103, DOI: 10.3390/jcm13133739.Peer-Reviewed Original ResearchAssisted reproductive technologyGrowth differentiation factor 9Follicle-stimulating hormoneEndometrial biomarkersAnti-Mullerian hormoneBone morphogenetic protein 15Differentiation factor 9Immune markersOvarian biomarkersART outcomesGene profilesReproductive technologyFactor 9Predicting outcomeBiomarkersCustomized implantsProteomic technologiesHormoneOutcomesClinical integration
2023
AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles
Li H, Seifer D, Tal R. AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles. Reproductive Biology And Endocrinology 2023, 21: 19. PMID: 36739415, PMCID: PMC9898926, DOI: 10.1186/s12958-023-01066-w.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneNumber of embryosEuploid embryosLive birthsOocyte qualityAge groupsSignificant independent predictorsCase-control analysisSART CORS databasePreimplantation genetic testingAMH levelsIVF cyclesIndependent predictorsIVF outcomesOocyte yieldNormal embryosPredictive roleGenetic testingFinal analysisBirthAgeIVFSubset of cyclesHormonePGT
2022
Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS
Shapiro A, Kushnir V, Seifer D. Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS. 2022, 511-525. DOI: 10.1007/978-3-030-92589-5_25.Peer-Reviewed Original ResearchPolycystic ovary syndromeAnti-Mullerian hormonePathophysiology of PCOSSerum anti-Mullerian hormoneElevated AMH levelsAvailable treatment modalitiesNovel therapeutic approachesFuture therapeutic targetsChronic anovulationOvulatory dysfunctionAMH levelsOvary syndromeOvulatory functionTreatment modalitiesNormal folliculogenesisTherapeutic approachesTherapeutic targetPatientsCritical roleAnovulationDysfunctionPathophysiologySyndromeFolliculogenesisHormone
2020
Anti-Müllerian hormone as a qualitative marker - or just quantity?
Kotlyar A, Seifer DB. Anti-Müllerian hormone as a qualitative marker - or just quantity? Current Opinion In Obstetrics & Gynecology 2020, 32: 219-226. PMID: 32205525, DOI: 10.1097/gco.0000000000000623.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneOvarian reserve testingClinical pregnancy rateLive birth rateOnset of menopausePremature ovarian insufficiencyNumber of oocytesSignificant predictive valueAMH levelsFertilization cyclesPregnancy rateOvarian insufficiencyIntracycle variabilityOocyte qualityPredictive valueEarly folliclesFetal trisomiesHormoneReproductive technologiesRiskQualitative markersSmall interMenopauseInsufficiencyFollicles8. Level of Anti-Müllerian Hormone and the Association of Vitamin D Deficiency with Polycystic Ovarian Syndrome in Adolescent Females
Simpson S, Seifer D, Shabanova V, Lynn A, Howe C, Rowe E, Caprio S, Vash-Margita A. 8. Level of Anti-Müllerian Hormone and the Association of Vitamin D Deficiency with Polycystic Ovarian Syndrome in Adolescent Females. Journal Of Pediatric And Adolescent Gynecology 2020, 33: 241-242. DOI: 10.1016/j.jpag.2020.01.067.Peer-Reviewed Original Research
2015
Assessing ovarian response: antral follicle count versus anti-Müllerian hormone
Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproductive BioMedicine Online 2015, 31: 486-496. PMID: 26283017, DOI: 10.1016/j.rbmo.2015.06.015.Peer-Reviewed Original ResearchConceptsAntral follicle countAnti-Müllerian hormoneAMH levelsOvarian reserveFollicle countOvarian responseFollicle numberPredictive valueSerum anti-Müllerian hormoneGood predictive valuePersonalization of treatmentGold standard biomarkerOvarian stimulationExogenous gonadotrophinsMenstrual cyclePoor responseHormone biomarkersOocyte numberUltrasound biomarkersBiomarkersAmerican SocietyGood responseSame ageHormoneStimulation
2013
Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone
Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertility And Sterility 2013, 99: 1825-1830. PMID: 23548941, DOI: 10.1016/j.fertnstert.2013.03.001.Peer-Reviewed Original Research
2010
Discordance between antimullerian hormone (AMH) and day 3 follicle stimulating (FSH) levels in the assessment of ovarian reserve
Leader B, Baca Q, Seifer D, Baker V. Discordance between antimullerian hormone (AMH) and day 3 follicle stimulating (FSH) levels in the assessment of ovarian reserve. Fertility And Sterility 2010, 94: s23. DOI: 10.1016/j.fertnstert.2010.07.088.Peer-Reviewed Original Research
1995
Endocrinology: Follicular fluid insulin-like growth factor-I and insulin-like growth factor-II concentrations vary as a function of day 3 serum follicle stimulating hormone*
Seifer DB, Giudice LC, Dsupin BA, Haning RV, Frishman GN, Burger HG. Endocrinology: Follicular fluid insulin-like growth factor-I and insulin-like growth factor-II concentrations vary as a function of day 3 serum follicle stimulating hormone*. Human Reproduction 1995, 10: 804-806. PMID: 7650124, DOI: 10.1093/oxfordjournals.humrep.a136042.Peer-Reviewed Original ResearchConceptsDay 3 serum follicleInsulin-like growth factorFollicular fluid concentrationsFSH groupSerum follicleIGF-IIGrowth factorFollicular fluid insulin-like growth factorMean IGF-II concentrationsFluid concentrationsMean IGF-I concentrationInsulin-like growth factor II concentrationsDay 3 FSHFollicular fluid IGFIGF-II concentrationsIGF-I concentrationsFactor II concentrationsFollicular fluid aspirationInhibin concentrationsFluid aspirationEmbryo transferFolliclesIGFHormoneGroup
1992
Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles
Penzias A, Shamma F, Gutmann J, Seifer D, DeCherney A, Lavy G. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles. Journal Of Assisted Reproduction And Genetics 1992, 9: 244-247. PMID: 1525454, DOI: 10.1007/bf01203821.Peer-Reviewed Original Research
1991
The Neuroendocrine Regulation of the Menstrual Cycle
Meyers-Seifer C, Seifer D. The Neuroendocrine Regulation of the Menstrual Cycle. Clinical Perspectives In Obstetrics And Gynecology 1991, 1-21. DOI: 10.1007/978-1-4612-3026-7_1.Peer-Reviewed Original Research